100%创新药的含金量！同类规模领先的港股通创新药ETF(159570)标的指数修订正式落地生效！

Core Insights - The Hong Kong Stock Connect Innovative Drug ETF (159570) has undergone a significant index revision, increasing the frequency of adjustments to four times a year and ensuring a 100% purity in its component stocks by excluding CXO companies [1][3] Group 1: Index Revision and Performance - The index now excludes eight CXO component stocks that collectively accounted for 17.35% of the index weight as of July 31 [1] - The ETF has seen a substantial increase in scale, exceeding 13.3 billion yuan, with over 2.5 billion yuan raised in the last ten days alone [2] - The index has demonstrated impressive performance, with a year-to-date increase of over 96% [2] Group 2: Industry Trends and Implications - The removal of CXO companies enhances the index's ability to reflect the trends in the domestic innovative drug sector, maximizing the capture of industry growth [3] - The innovative drug sector is experiencing a shift towards quality over price competition, supported by recent policy changes and a significant increase in business development (BD) transactions, which surpassed 60 billion USD in the first half of the year [5] - The index's adjustment aligns with the broader trend of China transitioning from a raw material supplier to a global hub for innovative drugs, enhancing the potential for capturing industry development benefits [5][6]